We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Reclassifies Apple’s ECG App into Lower-Risk Class II, Special Controls
FDA Reclassifies Apple’s ECG App into Lower-Risk Class II, Special Controls
Apple’s electrocardiograph (ECG) software for over-the-counter use, available as an app, has received a risk downgrade from the FDA to class II (special controls) as opposed to the highest-risk class III category.
To View This Article:
Login
Subscribe To Device Daily Bulletin Premium
Device Daily Bulletin Premium Subscription
Upgrade to Device Daily Bulletin Premium to get all the articles in the free publication PLUS more in-depth stories on regulatory and industry developments, FDA inspection and enforcement activities and analysis of market trends. It makes sense of everything successful devicemakers must know and do, delivering the news, analysis and interpretation of industry changes you need to stay compliant and thrive. And it’s combined with timely content from FDAnews management reports and webinars. Learn more
